43 results about "Malarial parasite" patented technology

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

According to the purposes of the present disclosure, as embodied and broadly described herein, the present disclosure relates, in one aspect, to scaffold molecules that exhibit potent anti-malarial activity against a variety of Plasmodium strains at different stages of a parasite, such as the red and infrared stages, and pharmaceutical compositions comprising the scaffold molecules. In one aspect, these compounds are tetrahydroacridones having Structure I described herein. In another aspect, the compounds described herein may be used to treat or prevent malaria in a subject.

The application discloses a kit for rapidly identifying malignant plasmodium based on an RPA-CRISPR / Cas12a fluorescence system and belongs to the field of detection and testing. The kit comprises a malignant plasmodium RPA specific primer pair, a crRNA fragment, a fluorescence reporter probe, and a buffer and Cas12a protein for a CRISPR reaction. The application is based on RPA technology, CRISPR / Cas12a technology and fluorescence detection technology, and a kit and a detection method for rapidly, accurately, simply and specifically detecting and identifying malignant plasmodium are constructed. The kit and the detection method can be used for detecting malignant plasmodium in a wild or clinical environment, especially in a country with limited resources, and the detection method does not require expensive instruments and equipment and a professional standard laboratory, and therefore has important significance for malaria monitoring, diagnosis and prevention and control.

This invention provides the application of Pulsatilla saponin B4 in the preparation of antimalarial drugs, which can significantly improve weight loss, peripheral blood parasitemia, and survival rate in mice infected with lethal Plasmodium. Its mechanism of action is not to directly kill Plasmodium, but to regulate the host immune system, including activating T / B cell immune responses, upregulating pro-inflammatory factors and interferon signaling pathways, and downregulating Arg1 expression. At the same time, Pulsatilla saponin B4 can alleviate immunopathological damage to organs such as the spleen and liver, restore the homeostasis of the spleen's immune microenvironment, and protect the normal structure of tissues. As a natural product, this compound has the characteristics of multiple targets and low toxicity, and has the dual advantages of anti-infection and immune homeostasis regulation, showing good prospects for clinical application and translation.

In one aspect, the present invention relates to compounds that inhibit asexual erythroid parasites (PfABS) of Plasmodium falciparum. In one aspect, these compounds exhibit sub-mmol potency against the erythroid phase of Plasmodium falciparum and other Plasmodium. In another aspect, these compounds are soluble in aqueous solutions at pH 7.4, making them suitable for oral administration by patients. Also disclosed are methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of treating or preventing malaria using the compounds. This abstract is intended as a scanning tool for a field-specific search and is not intended to be limiting of the present disclosure.

Disclosed herein are methods and compositions for treating and / or preventing Plasmodium falciparum malaria by administering a compound that mimics the binding of anti-Plasmodium falciparum Glutamic Acid Rich Protein (PfGARP).

In a method for diagnosing dengue fever and malaria, DNA extracted from a sample is added to a composition including a first primer set of nucleotide sequences of SEQ ID Nos. 1 to 6 and a second primer set of nucleotide sequences of SEQ ID Nos. 7 to 11, a loop-mediated isothermal amplification (LAMP) reaction of the DNA is performed to produce a colorimetric change, an image of the reaction tube is captured, the image is analyzed using a trained artificial intelligence model to determine whether the reaction indicates a positive or negative result for Dengue virus or Plasmodium falciparum.

An immunogen generally includes an immunogenic carrier that includes a virus-like particle (VLP) and an antigenic Anopheles spp. TRIO peptide that includes amino acids VDDLMAKFN (SEQ ID NO:1) or AANLRDKFN (SEQ ID NO:5) linked to the immunogenic carrier. The immunogen can be formulated into a composition such as vaccine. The composition or vaccine may be used to treat a subject having, or at risk of having malaria. The composition or vaccine may be used to treat a subject having Plasmodium falciparum blood stage parasitemia.

The present invention relates to a vaccine composition for preventing malaria, comprising, as an active ingredient, an elongation factor-2 (EF-2) recombinant protein derived from Plasmodium falciparum and, more specifically, to a vaccine composition for preventing malaria, comprising, as an active ingredient, EF-2 recombinant peptides derived from Plasmodium falciparum consisting of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively, and use thereof.

The present invention provides an antimalarial composition comprising arjunetin and artemisinin. The composition exhibits synergistic antimalarial effect against malaria causing Plasmodium species including Plamsodium falciparum, P berghe species. The composition comprising Arjunetin and Artemisinin demonstrated potent antimalarial activity in vivo and in vitro with better survival and low parasite burden in the blood.

In one aspect, the disclosure relates to compounds that inhibit Plasmodium falciparum asexual blood stage parasites (PfABS) In one aspect, the compounds exhibit sub-millimolar potency against the intraerythrocytic stages of Plasmodium falciparum and other Plasmodium species. In another aspect, the compounds are soluble in aqueous solutions at pH 7.4, making them suitable for oral administration to patients. Also disclosed are methods of making the compounds, pharmaceutical compositions comprising the same, and methods of treating or preventing malaria using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention relates to application of a scavenger receptor A antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention and treatment. Aiming at the technical problem that in the prior art, the drug resistance of plasmodium to drugs and the resistance of mosquito vector to insecticides are increasingly serious, so that the malaria propagation control effect is reduced, the invention provides a scavenger receptor A antibody which is specifically combined with a scavenger receptor A on the surface of macrophage to inhibit the phagocytic function of the scavenger receptor A, so that the control effect of malaria propagation is improved. Therefore, the proliferation of antimalarial active bacteria (such as Elizabeth, shigella sonnei or klebsiella oxytoca) in the stomach of the anopheles is promoted, and the development of plasmodium in the midgut of the anopheles is indirectly blocked. The antibody can be used alone or in combination with a Pfs25 antibody. The anopheles infection rate and the number of oocysts are remarkably reduced (for example, the infection rate is reduced from 81.7% to 6%), an eco-friendly biological control mode which is not prone to drug resistance is provided, and a new strategy is provided for malaria transmission blocking.

This disclosure relates to a compound represented by formula I:(I) and a method for treating malaria parasitic infection, the method comprising administering the compound represented by formula I or a pharmaceutically acceptable salt thereof to a person in need of such treatment. [Formula 1] TIFF2026520957000151.tif23115

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that exhibit potent antimalarial activity against multiple strains of Plasmodium spp. in the parasite's various stages, such as, for example, the erythrocytic and exoerythrocytic stages, and pharmaceutical compositions comprising same. In one aspect, the compounds are tetrahydroacridinones having the structure I described herein. In another aspect, the compounds described herein can be used to treat or prevent malaria in a subject.

The present invention relates to a multiplex and simultaneous antigen detection kit (200) for the rapid diagnosis of Dengue, Chikungunya, and two forms of Malaria (Plasmodium vivax and Plasmodium falciparum) from whole blood samples. Utilizing vertical flow technology, the kit allows the detection of multiple antigens concurrently, offering faster results with enhanced sensitivity and specificity compared to traditional lateral flow assays. The diagnostic device employs metal nanoparticles and gold conjugates to detect the specific antigens, facilitating co-infection detection without the need for serum or plasma separation.

This application relates to compositions comprising 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof for use in reducing or preventing the transmission of malaria and dengue fever, and corresponding methods. This application also relates to 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof for use in inhibiting the development of protozoa into ookinetes, oocysts, or sporozoites, and to mosquito baits comprising 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof and one or more sugar sources.

An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NANPNVDP (SEQ ID NO:2) linked to the immunogenic carrier. The immunogen may be administered to a subject having or at risk of having malaria. Alternatively, the immunogen may be administered to an individual having or at risk of having Plasmodium falciparum blood stage parasitemia. In some cases, the immunogen can be administered in combination with another therapeutic agent for treating malaria of Plasmodium falciparum blood stage parasitemia.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

This invention relates to compounds, compositions and methods for preventing or treating malaria by modulating immune responses through Killer-specific Secretory Protein 37 (Ksp37). The invention provides for the administration of Ksp37, or stimulation of endogenous Ksp37 production using polar compounds such as DMF or DMSO, to increase Ksp37 levels in a subject to therapeutically effective concentrations. Elevated Ksp37 enhances cytotoxic CD8+ T-cell and NK-cell activity, supports cytokine balance, and improves immune clearance of Plasmodium parasites during both liver and blood stages. These approaches promote targeted immune activation, reduce parasite survival, and improve host protection against malaria infection.

Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naïve, G6PD-normal subjects.

The application discloses a method for typing and identifying malaria parasites based on multi-scale feature extraction and confidence weighting, which combines the advantages of thick blood film and thin blood film dual-mode recognition on the basis of the Ultralytics YOLOv11 model. First, the malaria parasite characteristic digital enhancement modulation strengthens the features, and multi-scale feature extraction and result cleaning are respectively performed on thick blood films (adapted to 9 types of labels) and thin blood films (adapted to 18 types of labels). Then, based on the confidence and quantity weighting rules, preliminary determination of thick blood film positive and negative and preliminary determination of thin blood film typing are completed. Finally, through cross-blood film feature fusion and comprehensive weighted determination, positive and negative and typing confirmation are realized, and artificial experience digital rules are integrated. The method solves the limitations of single blood film recognition, takes into account the screening sensitivity and identification accuracy, and improves the efficiency and accuracy of malaria parasite recognition and typing.

The invention provides a lysis buffer for targeted removal of red blood cells, a red blood cell lysis method and application thereof, and belongs to the technical field of red blood cell lysis. The lysate consists of a plasmodium merozoite extract, soybean plant hemagglutinin and a liquid-based cell preservation solution, wherein the liquid-based cell preservation solution is an aqueous solution containing glycyrrhizic acid, disodium ethylene diamine tetraacetate, disodium hydrogen phosphate, sodium chloride, potassium chloride and monopotassium phosphate. According to the method disclosed by the invention, the plasmodium merozoite extract and the soybean plant hemagglutinin are combined to quickly degrade protein and lipid which are key components of an erythrocyte membrane and destroy the integrity of a membrane structure, so that erythrocyte rupture is finally caused, and no adverse effect is caused on visible components such as other cells while the erythrocyte is efficiently and quickly removed.

Non-naturally occurring circumsporozoite protein (CSP) antigens are provided, comprising an amino acid sequence at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the ammo acid sequence selected from the group consisting of SEQ ID NO: 1-38, or an antigenic fragment thereof, as are fusion proteins thereof, nanoparticles thereof, and methods for their use in treating or limiting development of a Plasmodium falciparum infection.

To provide methods and compositions for treating and preventing malaria.SOLUTION: The present disclosure provides immunogenic compositions for inducing an immune response against malaria. The present disclosure also provides novel methods of administering the immunogenic compositions. Disclosed herein are methods and compositions for treating malaria by administering an immunogenic composition. The compositions benefit from the use of saponin-based adjuvants which provide particularly enhanced immune responses. In embodiments, provided herein are immunogenic compositions comprising an antigen of a Plasmodium parasite.SELECTED DRAWING: None

Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as Plasmodium falciparum.

Disclosed herein are methods and apparatus for making a determination whether a blood sample is, or is not, infected with a malaria parasite. The determination is made using a trained machine-learning (ML) algorithm. In some aspects, a microfluidic chip is used for the concentration of red blood cells infected with these parasites from uninfected red blood cells, the staining of the blood sample which differentially stains infected and uninfected red blood cells, and holds the sample of interest for imaging. The microfluidic chip is inserted into an optical subsystem that magnifies the image created from transmitted light microscopy. The magnified image is captured with a camera, and a trained ML algorithm assesses if the sample does or does not contain the parasite. Generally, the ML algorithm is executed on a portable computing device such as a smartphone.

Compositions and methods for treating malaria are provided, utilizing antimicrobial peptides (AMPs) targeting malaria parasites (particularly Plasmodium falciparum (Pff). The AMPs of the provided compositions and methods penetrate red blood cells infected with the parasites with high selectivity, while sparing non-infected cells, and are characterized by reduced risk of drug resistance. Further provided are novel peptides targeting the malaria parasite Plasmodium falciparum (Pf) which are particularly effective as anti-malaria agents.